Skip to main content
    Q

    Quest Diagnostics Incorporated (DGX)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $262.26
    +2.66 (+1.02%)

    Market Cap: $28.56B

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Quest Diagnostics Incorporated (DGX) Financials: Revenue, Profit and Cash Flow

    Updated Oct 22, 2026. Financial statements from company filings, amounts in US dollars.

    Quest Diagnostics reported revenue of $11.04B for the fiscal year ended Dec 31, 2025, up 11.8% from the year before. That year, net income was $1.05B with a net margin of 9.5%, operating cash flow was $1.89B and free cash flow was $1.36B. The quarter ended Sep 30, 2026 had revenue of $3.10B and net income of $326.00M.

    Revenue and Margins

    The operating margin was 14.1% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $7.21B, a compound annual rate of 4.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$11.04B+11.8%33.2%14.1%9.5%
    Dec 2024$9.87B+6.7%32.9%13.6%9.3%
    Dec 2023$9.25B-6.4%33.0%13.6%9.8%
    Dec 2022$9.88B-8.4%34.7%14.4%10.3%
    Dec 2021$10.79B+14.3%39.0%22.1%19.3%
    Dec 2020$9.44B+22.1%38.5%20.9%15.9%
    Dec 2019$7.73B+2.6%34.8%15.9%11.7%
    Dec 2018$7.53B+1.7%34.6%14.6%10.5%
    Dec 2017$7.40B+2.6%36.2%15.7%11.1%
    Dec 2016$7.21BN/A36.0%17.7%9.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 14.0% from the year before. In the quarter ended Sep 2026, net income rose 25.9% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$11.04B$9.87B$9.25B$9.88B$10.79B$9.44B$7.73B$7.53B$7.40B$7.21B
    Cost of revenue$7.37B$6.63B$6.20B$6.45B$6.58B$5.80B$5.04B$4.93B$4.72B$4.62B
    Gross profit$3.67B$3.24B$3.05B$3.43B$4.21B$3.63B$2.69B$2.60B$2.68B$2.60B
    Operating income$1.56B$1.35B$1.26B$1.43B$2.38B$1.97B$1.23B$1.10B$1.17B$1.28B
    Net income$1.05B$921.00M$908.00M$1.01B$2.08B$1.50B$906.00M$788.00M$824.00M$696.00M
    EBITDA$2.15B$1.87B$1.72B$1.81B$3.16B$2.41B$1.58B$1.40B$1.45B$1.48B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$3.10B$3.04B$2.90B$2.81B$2.82B$2.76B$2.65B$2.62B$2.49B$2.40B$2.37B$2.29B
    Gross profit$1.04B$1.03B$942.00M$910.00M$949.00M$943.00M$863.00M$858.00M$811.00M$804.00M$771.00M$736.00M
    Operating income$479.00M$459.00M$399.00M$386.00M$386.00M$438.00M$346.00M$361.00M$330.00M$355.00M$300.00M$267.00M
    Net income$326.00M$334.00M$264.00M$256.00M$259.00M$296.00M$235.00M$236.00M$237.00M$240.00M$208.00M$205.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $5.67B exceeded cash and equivalents by $5.25B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$16.23B$16.15B$14.02B$12.84B$13.61B$14.03B$12.84B$11.00B$10.50B$10.10B
    Current assets$2.38B$2.39B$2.37B$1.90B$2.74B$3.06B$2.49B$1.39B$1.31B$1.53B
    Cash and equivalents$420.00M$549.00M$686.00M$315.00M$872.00M$1.16B$1.19B$135.00M$137.00M$359.00M
    Total liabilities$8.94B$9.26B$7.60B$6.83B$7.05B$7.13B$7.08B$5.66B$5.47B$5.36B
    Short-term debt$504.00M$602.00M$303.00M$2.00M$2.00M$2.00M$804.00M$464.00M$36.00M$6.00M
    Long-term debt$5.17B$5.62B$4.41B$3.98B$4.01B$4.01B$3.97B$3.43B$3.75B$3.73B
    Shareholder equity$7.17B$6.78B$6.31B$5.89B$6.44B$6.76B$5.64B$5.22B$4.92B$4.63B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$17.22B$16.94B$16.67B$16.23B$16.20B$15.97B$15.80B$16.15B$16.09B$13.88B$13.95B$14.02B
    Total liabilities$9.19B$9.04B$8.93B$8.94B$8.82B$8.62B$8.75B$9.26B$9.17B$7.15B$7.41B$7.60B
    Cash and equivalents$797.00M$626.00M$393.00M$420.00M$432.00M$319.00M$188.00M$549.00M$764.00M$271.00M$474.00M$686.00M
    Shareholder equity$7.63B$7.52B$7.37B$7.17B$7.26B$7.23B$6.93B$6.78B$6.81B$6.62B$6.43B$6.31B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 72.0% of operating cash flow. Dividends and share repurchases together came to 63.2% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$1.89B$1.33B$1.27B$1.72B$2.23B$2.00B$1.24B$1.20B$1.18B$1.12B
    Capital expenditures$527.00M$425.00M$408.00M$404.00M$403.00M$418.00M$400.00M$383.00M$252.00M$293.00M
    Free cash flow$1.36B$909.00M$864.00M$1.31B$1.83B$1.59B$843.00M$817.00M$923.00M$823.00M
    Dividends paid$409.00M$378.00M$371.00M$378.00M$408.00M$355.00M$340.00M$320.00M$298.00M$264.00M
    Share repurchases$450.00M$151.00M$275.00M$1.41B$2.20B$325.00M$353.00M$322.00M$465.00M$590.00M
    Investing cash flow-$631.00M-$2.55B-$1.06B-$543.00M$21.00M-$772.00M-$411.00M-$801.00M-$830.00M-$127.00M
    Financing cash flow-$1.39B$1.08B$160.00M-$1.73B-$2.54B-$1.27B$225.00M-$401.00M-$592.00M-$738.00M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$611.00M$597.00M$278.00M$465.00M$563.00M$544.00M$314.00M$464.00M$356.00M$360.00M$154.00M$527.00M
    Capital expenditures$166.00M$138.00M$114.00M$158.00M$144.00M$108.00M$117.00M$123.00M$106.00M$92.00M$104.00M$72.00M
    Free cash flow$445.00M$459.00M$164.00M$307.00M$419.00M$436.00M$197.00M$341.00M$250.00M$268.00M$50.00M$455.00M
    Last 12 quarters

    Frequently Asked Questions About DGX

    What is Quest Diagnostics' annual revenue?

    Quest Diagnostics reported revenue of $11.04B for the fiscal year ended Dec 31, 2025.

    How fast is Quest Diagnostics' revenue growing?

    Revenue was up 11.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 3.7%.

    Is Quest Diagnostics profitable?

    Yes. Quest Diagnostics reported net income of $1.05B for the fiscal year ended Dec 31, 2025, with a net margin of 9.5%.

    How much free cash flow does DGX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $1.89B minus capital expenditures of $527.00M produced free cash flow of $1.36B.

    How much debt does Quest Diagnostics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $5.17B, short-term debt of $504.00M and cash and equivalents of $420.00M.